• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Hannon Armstrong Appoints Former EXIM Chairman Kimberly A. Reed and CEO Jeffrey A. Lipson to Board of Directors

    3/1/23 8:30:00 AM ET
    $HASI
    $MNTS
    $TAK
    Finance/Investors Services
    Finance
    Military/Government/Technical
    Industrials
    Get the next $HASI alert in real time by email

    Hannon Armstrong Sustainable Infrastructure Capital, Inc. ("Hannon Armstrong" or "HASI") (NYSE:HASI), a leading investor in climate solutions, today announced the appointment of Kimberly A. Reed and Jeffrey A. Lipson to its Board of Directors, effective March 1, 2023.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230301005447/en/

    Kimberly A. Reed (Photo: Business Wire)

    Kimberly A. Reed (Photo: Business Wire)

    In connection with these elections, the Board of Directors will consist of 11 members, 9 of whom are independent members. The Board appointed Ms. Reed to serve as a member of the Audit Committee and the Finance and Risk Committee.

    "We are delighted to add Kimberly Reed's talent and perspective to our Board as HASI continues to grow in ambition and scale," said Jeffrey W. Eckel, HASI Executive Chair. "Kimberly's demonstrated leadership in resurrecting and running the U.S. Export-Import Bank adds important government and regulatory experience and global connectivity to our Board, as well as another seasoned financial services voice."

    Ms. Reed said, "Hannon Armstrong Sustainable Infrastructure Capital, Inc.— the very first U.S. public company to focus solely on investments in energy efficiency, renewable energy, and other sustainable infrastructure markets and now with more than $9 billion in managed assets — plays a unique and pivotal role in the renewables firmament. HASI is led by a team that collectively brings unparalleled longevity in this rapidly evolving space, and I am confident that my experience leading major public agencies and engaging with diverse businesses across the United States will complement this superior team and the company's already substantive Board of Directors."

    Ms. Reed currently serves on the Board of Directors of Takeda Pharmaceutical Company Limited (NYSE:TAK) and Momentus Inc. (NASDAQ:MNTS) and is a distinguished fellow with the Council on Competitiveness.

    Ms. Reed served as the first woman chairman of the Board of Directors, president and chief executive officer of the Export-Import Bank of the United States (EXIM) — the nation's official $135 billion export credit agency — from 2019 to 2021 after being confirmed by the U.S. Senate with overwhelming bipartisan support. As EXIM chairman, she worked to help U.S. companies — including those in the renewable and clean energy and transformational technology sectors —succeed in the competitive global marketplace. Earlier in her career, Ms. Reed was president of the International Food Information Council Foundation, where she worked with multi-national food and agribusiness companies on nutrition, health, and sustainability issues; senior advisor to U.S. Treasury Secretaries Henry Paulson and John Snow; chief executive officer of the Community Development Financial Institutions Fund (CDFI Fund); and counsel to three committees of the U.S. Congress, where she conducted oversight and investigations.

    She also currently serves on the American Swiss Foundation Board of Directors, Hudson Institute's Alexander Hamilton Commission on Securing America's National Security Innovation Base, Krach Institute for Tech Diplomacy at Purdue Advisory Council and Indiana University School of Public Health-Bloomington Dean's Alliance.

    Recognized as one of the "100 Women Leaders in STEM," Ms. Reed received the U.S. Department of Defense's highest civilian award — the Medal for Distinguished Public Service — and is a Council on Foreign Relations life member and National Association of Corporate Directors (NACD) Certified Director. She holds a Juris Doctor from West Virginia University College of Law and a Bachelor of Science in biology and a Bachelor of Arts in government from West Virginia Wesleyan College.

    "We also welcome our new CEO, Jeff Lipson, on the Board," Mr. Eckel added. As previously announced, Jeffrey A. Lipson has transitioned to the role of president and chief executive officer of HASI effective today. Mr. Lipson served as both chief operating officer and chief financial officer of HASI from January 2021 to February 2023, and chief financial officer from January 2019 to December 2020.

    About Hannon Armstrong

    Hannon Armstrong (NYSE:HASI) is the first U.S. public company solely dedicated to investments in climate solutions, providing capital to assets developed by leading companies in energy efficiency, renewable energy, and other sustainable infrastructure markets. With more than $9 billion in managed assets, our core purpose is to make climate positive investments with superior risk-adjusted returns. For more information, please visit hannonarmstrong.com or follow us on Twitter and LinkedIn.

    Forward-Looking Statements

    Some of the information contained in this press release is forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended that are subject to risks and uncertainties. For these statements, we claim the protections of the safe harbor for forward-looking statements contained in such Sections. These forward-looking statements include information about possible or assumed future results of our business, financial condition, liquidity, results of operations, plans and objectives. When we use the words "believe," "expect," "anticipate," "estimate," "plan," "continue," "intend," "should," "may" or similar expressions, we intend to identify forward-looking statements.

    Forward-looking statements are subject to significant risks and uncertainties. Investors are cautioned against placing undue reliance on such statements. Actual results may differ materially from those set forth in the forward-looking statements. Factors that could cause actual results to differ materially from those described in the forward-looking statements include those discussed under the caption "Risk Factors" included in our most recent Annual Report on Form 10-K as well as in other periodic reports that we file with the U.S. Securities and Exchange Commission

    Forward-looking statements are based on beliefs, assumptions and expectations as of the date of this press release. We disclaim any obligation to publicly release the results of any revisions to these forward-looking statements reflecting new estimates, events or circumstances after the date of this press release.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20230301005447/en/

    Get the next $HASI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HASI
    $MNTS
    $TAK

    CompanyDatePrice TargetRatingAnalyst
    Takeda Pharmaceutical Company Limited
    $TAK
    4/8/2026Mkt Perform → Outperform
    Bernstein
    HA Sustainable Infrastructure Capital Inc.
    $HASI
    2/17/2026$40.00 → $50.00Buy
    TD Cowen
    Takeda Pharmaceutical Company Limited
    $TAK
    1/13/2026Overweight
    Morgan Stanley
    Takeda Pharmaceutical Company Limited
    $TAK
    4/2/2025Equal-Weight → Overweight
    Morgan Stanley
    HA Sustainable Infrastructure Capital Inc.
    $HASI
    2/27/2025$33.00Overweight
    Wells Fargo
    HA Sustainable Infrastructure Capital Inc.
    $HASI
    2/6/2025$40.00Buy
    Truist
    HA Sustainable Infrastructure Capital Inc.
    $HASI
    1/8/2025$36.00Neutral → Buy
    Citigroup
    HA Sustainable Infrastructure Capital Inc.
    $HASI
    11/25/2024$40.00Buy
    BofA Securities
    More analyst ratings

    $HASI
    $MNTS
    $TAK
    SEC Filings

    View All

    HA Sustainable Infrastructure Capital Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

    8-K - HA Sustainable Infrastructure Capital, Inc. (0001561894) (Filer)

    7/20/26 8:00:48 AM ET
    $HASI
    Finance/Investors Services
    Finance

    SEC Form 6-K filed by Takeda Pharmaceutical Company Limited

    6-K - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Filer)

    7/9/26 6:00:29 AM ET
    $TAK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Takeda Pharmaceutical Company Limited

    6-K - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Filer)

    7/8/26 6:02:00 AM ET
    $TAK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HASI
    $MNTS
    $TAK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    HASI Announces Second Quarter 2026 Earnings Release Date and Conference Call

    HA Sustainable Infrastructure Capital, Inc. ("HASI," "We," "Our," or the "Company") (NYSE:HASI), a leading investor in sustainable infrastructure assets, today announced that the Company will release its second quarter 2026 results after market close on Thursday, August 6, 2026, to be followed by a conference call at 5:00 p.m. (Eastern Time). The conference call can be accessed live over the phone by dialing 1-877-407-0890 (Toll-Free) or +1-201-389-0918 (toll). Participants should inform the operator they would like to join the "HASI Second Quarter 2026 Results" call. The conference call will also be accessible as an audio webcast with slides, which interested investors and other parties

    7/20/26 7:00:00 AM ET
    $HASI
    Finance/Investors Services
    Finance

    Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies

    On average, about 75% of patients with scalp psoriasis treated with zasocitinib achieved clear or almost clear skin at week 16 Approximately 70% of patients with palmoplantar disease treated with zasocitinib achieved clear or almost clear skin at week 16 Zasocitinib demonstrated statistically significant improvements in Nail Psoriasis Severity Index (NAPSI) versus placebo Results reinforce the potential of zasocitinib to deliver rapid and durable skin clearance, including in the hardest-to-treat areas, in a convenient once-daily pill Takeda ((TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and potent ora

    7/16/26 6:00:00 PM ET
    $TAK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Takeda and the Indonesian Government Announce Landmark Collaboration to Strengthen Healthcare Resilience and Expand Access to Lifesaving Plasma-Derived Medicinal Products

    Ministry of Health of the Republic of Indonesia Grants Plasma Fractionation License, Enabling Takeda to Collect and Fractionate Plasma as Part of Multi-Phased Initiative Takeda Will Initially Invest up to 30 Million U.S. Dollars to Begin the Establishment of an Ecosystem for Plasma-Derived Medicinal Products, including a pilot of a National Plasma Donation Network Collaboration Builds on Decades-Long Relationship Between Takeda and Indonesia Focused on Elevating Healthcare Standards for Patients Takeda (NYSE:TAK) and the Indonesian Government (the Ministry of Health, the Ministry of Investment and Downstream Industry/BKPM and the Coordinating Ministry for Economic Affairs) today a

    7/12/26 7:00:00 PM ET
    $TAK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HASI
    $MNTS
    $TAK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Gillis Steven was granted 3,800 units of Ordinary Shares, increasing direct ownership by 58% to 10,400 units (SEC Form 4) to satisfy withholding obligation

    4 - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Issuer)

    7/6/26 6:29:03 PM ET
    $TAK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Maraganore John was granted 3,800 units of Ordinary Shares, increasing direct ownership by 58% to 10,400 units (SEC Form 4) (for withholding tax)

    4 - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Issuer)

    7/6/26 6:28:41 PM ET
    $TAK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Reed Kimberly A. was granted 3,800 units of Ordinary Shares, increasing direct ownership by 58% to 10,400 units (SEC Form 4) (tax withholding)

    4 - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Issuer)

    7/6/26 6:28:22 PM ET
    $TAK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HASI
    $MNTS
    $TAK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $HASI
    $MNTS
    $TAK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Director Hadfield Chris bought $14,380 worth of shares (2,000 units at $7.19) (SEC Form 4)

    4 - Momentus Inc. (0001781162) (Issuer)

    5/26/26 2:54:53 PM ET
    $MNTS
    Military/Government/Technical
    Industrials

    Director Kabot Brian bought $1,379 worth of shares (250 units at $5.51), increasing direct ownership by 6% to 4,708 units (SEC Form 4)

    4 - Momentus Inc. (0001781162) (Issuer)

    5/22/26 2:55:51 PM ET
    $MNTS
    Military/Government/Technical
    Industrials

    Director Kabot Brian bought $1,404 worth of shares (250 units at $5.62) and converted options into 913 shares, increasing direct ownership by 35% to 4,458 units (SEC Form 4)

    4 - Momentus Inc. (0001781162) (Issuer)

    5/20/26 8:34:05 PM ET
    $MNTS
    Military/Government/Technical
    Industrials

    Takeda Pharma upgraded by Bernstein

    Bernstein upgraded Takeda Pharma from Mkt Perform to Outperform

    4/8/26 9:38:13 AM ET
    $TAK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TD Cowen reiterated coverage on Hannon Armstrong Sust. Infr. with a new price target

    TD Cowen reiterated coverage of Hannon Armstrong Sust. Infr. with a rating of Buy and set a new price target of $50.00 from $40.00 previously

    2/17/26 7:03:18 AM ET
    $HASI
    Finance/Investors Services
    Finance

    Morgan Stanley resumed coverage on Takeda Pharma

    Morgan Stanley resumed coverage of Takeda Pharma with a rating of Overweight

    1/13/26 8:31:07 AM ET
    $TAK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HASI
    $MNTS
    $TAK
    Leadership Updates

    Live Leadership Updates

    View All

    Takeda Announces New Assignments of Directors and Appointment of Julie Kim as Representative Director, President and CEO

    Board of Directors appoints Julie Kim as Representative Director, President & CEO following shareholder vote Announces new appointments and assignments of directors   In the final step of its 18-month CEO transition, Takeda ((4502, NYSE:TAK) today announced that Julie Kim was officially appointed Takeda’s Representative Director, President and Chief Executive Officer. During the 150th Annual General Meeting of Shareholders, which took place in Osaka, Japan, shareholders elected Julie as a new internal director to the Board of Directors. Following the vote and conclusion of the meeting, the Board of Directors appointed her as Representative Director, President & CEO. Upon conclusi

    6/24/26 3:05:00 AM ET
    $TAK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HASI Announces Executive Appointments

    HA Sustainable Infrastructure Capital, Inc. ("HASI," "we" or "our") (NYSE:HASI) today announced executive appointments, effective May 12, 2026. "I am pleased to announce these management changes and promotions as we continue to recruit and retain top talent to drive our ongoing success," said Jeffrey A. Lipson, President and Chief Executive Officer of HASI. "All of these individuals are accomplished executives with a collaborative approach, and I am extremely confident that each will thrive in their new roles." Amanuel Haile-Mariam will assume the role of Senior Managing Director and Co-Chief Investment Officer. Mr. Haile-Mariam joined HASI in 2021 and has successfully grown our Grid-Co

    5/7/26 4:07:00 PM ET
    $HASI
    Finance/Investors Services
    Finance

    Alan Walshe Appointed General Manager of Takeda Canada

    A proven people‑focused commercial strategist with extensive global experience to lead Takeda Canada's next chapter of growth and impact.TORONTO, March 2, 2026  /CNW/ - Takeda Canada Inc. ("Takeda Canada") is pleased to announce the appointment of Alan Walshe as General Manager for Canada. Alan brings 17 years of experience with Takeda and its predecessor companies, most recently serving as Global Head of Commercial Strategy for the Plasma‑Derived Therapies Business Unit."Alan's depth of commercial expertise and global perspective, combined with his people‑focused leadership sty

    3/2/26 7:59:00 AM ET
    $TAK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HASI
    $MNTS
    $TAK
    Financials

    Live finance-specific insights

    View All

    HASI Announces Second Quarter 2026 Earnings Release Date and Conference Call

    HA Sustainable Infrastructure Capital, Inc. ("HASI," "We," "Our," or the "Company") (NYSE:HASI), a leading investor in sustainable infrastructure assets, today announced that the Company will release its second quarter 2026 results after market close on Thursday, August 6, 2026, to be followed by a conference call at 5:00 p.m. (Eastern Time). The conference call can be accessed live over the phone by dialing 1-877-407-0890 (Toll-Free) or +1-201-389-0918 (toll). Participants should inform the operator they would like to join the "HASI Second Quarter 2026 Results" call. The conference call will also be accessible as an audio webcast with slides, which interested investors and other parties

    7/20/26 7:00:00 AM ET
    $HASI
    Finance/Investors Services
    Finance

    Takeda Announces FY2025 Full Year Results and FY2026 Outlook, Highlighted by Excellent Pipeline Progress and Solid FY2025 Results

    FY2025 Pipeline Successes Set the Stage for Pivotal Product Launches Achieved Latest FY2025 Management Guidance Takeda is Entering a New Era & Transforming for Growth Acceleration   Takeda ((4502, NYSE:TAK) today announced financial results for the fiscal year 2025 (period ended March 31, 2026). The Company delivered solid results in line with its latest FY2025 Management Guidance, reflecting strong OPEX savings, mitigating revenue headwinds while continuing to invest in future growth. Key Highlights for FY2025 Revenue decreased by 1.7% YoY at actual exchange rates (AER), resulting from the loss of exclusivity for VYVANSE® which was partially mitigated by Growth and Launch

    5/13/26 2:38:00 AM ET
    $TAK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HASI Announces First Quarter 2026 Results With 20% Y/Y Growth in Adjusted EPS and Record Adjusted ROE of 15.7%

    HA Sustainable Infrastructure Capital, Inc. ("HASI," "we," "our" or the "Company") (NYSE:HASI), a leading investor in sustainable infrastructure assets, today reported results for the first quarter of 2026. Key Highlights GAAP EPS of $(0.57), compared with $0.44 in Q1 2025, and Adjusted EPS of $0.77, compared to $0.64 in Q1 2025. GAAP-based Net Investment Income (Loss) was $(6.9) million in Q1, and Adjusted Recurring Net Investment Income totaled $101 million in Q1, up 29% year-over-year. GAAP-based ROE was (11.4)% in Q1 2026, and Adjusted ROE increased to 15.7% in Q1. Managed Assets grew 13% year-over-year to $16.4 billion as of March 31, 2026. Closed more than $600 millio

    5/7/26 4:05:00 PM ET
    $HASI
    Finance/Investors Services
    Finance

    $HASI
    $MNTS
    $TAK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Momentus Inc.

    SC 13G/A - Momentus Inc. (0001781162) (Subject)

    11/14/24 5:14:58 PM ET
    $MNTS
    Military/Government/Technical
    Industrials

    Amendment: SEC Form SC 13G/A filed by Momentus Inc.

    SC 13G/A - Momentus Inc. (0001781162) (Subject)

    11/14/24 5:14:34 PM ET
    $MNTS
    Military/Government/Technical
    Industrials

    Amendment: SEC Form SC 13G/A filed by HA Sustainable Infrastructure Capital Inc.

    SC 13G/A - HA Sustainable Infrastructure Capital, Inc. (0001561894) (Subject)

    11/8/24 10:52:39 AM ET
    $HASI
    Finance/Investors Services
    Finance